Obsessive-Compulsive Disorder (OCD) affects approximately 2% of the global population, and only about half of patients respond adequately to conventional treatments. This unmet need has motivated investigation of novel therapeutic approaches. The present open-label, waitlist-controlled randomized trial evaluated the feasibility, safety, and preliminary efficacy of repeated psilocybin administration in adults with OCD who had previously attempted pharmacotherapy or evidence-based psychotherapy such as exposure and response prevention (ERP).
This study was conducted at the Johns Hopkins University School of Medicine as a waitlist-controlled, open-label randomized clinical trial. A total of 37 participants were randomized by age, sex, and baseline OCD severity. The design included an immediate-treatment arm and a waitlist-control arm; participants in the waitlist arm received identical treatment after an 8-week waiting period. The research is a preprint and has not been peer reviewed.
Thirty-seven participants were enrolled (mean age 38.4 years, SD 11.6; 21 female, 56.75%). Thirty participants (81.08% of those enrolled) completed the 1-month follow-up assessment. All participants had previously failed an adequate trial of either pharmacotherapy or evidence-based psychotherapy for OCD. Detailed inclusion and exclusion criteria were not reported in the abstract.
Participants received two supervised psilocybin dosing sessions spaced over two weeks. The first session used a 20 mg dose; the second session used a 30 mg dose if the first dose was well-tolerated. Sessions were delivered under supportive conditions. The immediate-treatment arm received the drug within one month of enrollment; the waitlist-control arm received the same supportive intervention and dosing after the 8-week wait period.
The primary clinician-rated outcome was the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), collected one week after each drug administration and one month after the second session. Self-report measures assessed acute subjective experiences and broader symptom domains, including the Mystical Experience Questionnaire (MEQ), Challenging Experience Questionnaire (CEQ), the 11-Dimensional Altered States of Consciousness (11D-ASC), State-Trait Anxiety Inventory (STAI), Beck Depression Inventory-II (BDI-II), and Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q).
Comparative analysis showed that the immediate-treatment group (N=16) had a greater reduction in Y-BOCS scores compared with the waitlist group (N=14), with a reported F statistic F(2,56)=16.17 and p<0.001. After the waitlist group crossed over to receive psilocybin, symptom improvement persisted at one month following the second psilocybin session for both groups (F(3,84)=29.91, p<0.001). The abstract reports that reductions in Y-BOCS after dosing sessions correlated with several measures of acute subjective experience, including total MEQ scores and individual factors within CEQ and 11D-ASC.
The authors report that two successive psilocybin doses administered over two weeks were well-tolerated in this sample. Thirty of 37 participants completed the 1-month follow-up. The abstract does not provide a detailed adverse event table or a breakdown of specific adverse events, so comprehensive safety profiling beyond the statement of tolerability is not available from the summary.
Analyses described in the abstract indicate that reductions in OCD symptoms (Y-BOCS) were correlated with acute subjective effect measures. Specifically, total scores on the MEQ and particular factors from the CEQ and 11D-ASC showed associations with symptom change. These findings suggest that the phenomenology of the psilocybin experience may relate to therapeutic response in OCD, as measured in this trial.
This report is a preprint and the trial was open-label without a blinded placebo control, which introduces potential expectancy and observer biases. The waitlist-control design partially addresses time-related change but does not replace double-blind placebo-controlled evidence. Detailed safety data and long-term outcomes beyond one month post-second session are not reported in the abstract. Findings are preliminary but support further controlled investigation of multidose psilocybin protocols for treatment-resistant OCD.
The trial is registered on ClinicalTrials.gov (Identifier NCT05546658). Ethical approval was provided by the Johns Hopkins School of Medicine Institutional Review Board (IRB00284207). The authors state that all necessary participant consent and institutional approvals were obtained. All data produced in the study are available upon reasonable request to the authors.
The study received philanthropic support from Charlie Scheeler and Mary Ellen Pease. Several authors declared competing interests: consulting relationships, advisory roles, stock holdings, DSMB service, research support from NIH and foundations, and other relevant activities described in the competing interest statement. The abstract notes that this work is a preprint and has not yet been certified by peer review.